TNFRSF9 and lung cancer: However, the ILA prevalence among patients with lung cancer varies from 3.9% among patients with stage IV NSCLC, as reported by Araki et al. [14], to 21.7% among patients with stage I and II lung cancer, as reported by Iwasawa et al. [15].